If you have been reading about reversed-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Researchers have been unable to exceed this average read size; like chain-termination sequencing alone, MS-based DNA sequencing may not be suitable for large de novo sequencing projects. Even so, a 2010 study did use the short sequence reads and mass spectroscopy to compare single-nucleotide polymorphisms in pathogenic Streptococcus strains.
Bugs then shows Neo her crew in an abandoned theater. Morpheus, part of Bugs' group once again, offers a blue pill and a red pill to Neo, who takes the red pill. The team then "unplugs" Neo and with the help of a friendly machine, who was hacked, he is revived in the real world inside Bugs' ship, the Mnemosyne. In the real world, after Morpheus helps Neo regain his memories and fighting style, the Mnemosyne goes to Io, the last human city led by Niobe. Niobe reveals that, when Zion was nearly destroyed by the machines in another war, she and the rest of the inhabitants escaped and made a new city with the help of some machines. After sixty years, Niobe does not trust Neo, but lets the Mnemosyne crew destroy the Matrix with the help of Sati, the sentient program who helped Neo in Revolutions. In the Matrix, Neo's therapist, named the Analyst, a program designed to study the human psyche and the new leader of both the Matrix and the machines, explains that after Neo and Trinity's deaths, he was able to resurrect them to study them. He found that suppressing their memories but keeping them close to one another made the Matrix more power-efficient and more resistant to the anomalies that caused the previous iterations to fail. However, Neo's liberation destabilized the system and triggered a fail-safe to reboot the Matrix. The Analyst stalled the reboot by convincing his superiors that threatening to kill Trinity would get Neo to voluntarily return to his pod.
=== Center for Biosecurity at UPMC === The Center for Biosecurity at UPMC (CBUPMC) is led by Thomas V. Inglesby, MD. Their mandate is to conduct "independent research, analysis, and nonpartisan policy recommendations" to serve as "resources for decision makers who are responsible for strengthening US planning, response, and resilience to catastrophic events."
== Criticism == The use of protective groups is pervasive but not without criticism. In practical terms their use adds two steps (protection-deprotection sequence) to a synthesis, either or both of which can dramatically lower chemical yield. Crucially, added complexity impedes the use of synthetic total synthesis in drug discovery. In contrast biomimetic synthesis does not employ protective groups. As an alternative, Baran presented a novel protective-group free synthesis of the compound hapalindole U. The previously published synthesis according to Baran, contained 20 steps with multiple protective group manipulations (two confirmed):
Sources: en.wikipedia.org
=== Dried === Some BCG vaccines are freeze dried and become fine powder. Sometimes the powder is sealed with vacuum in a glass ampoule. Such a glass ampoule has to be opened slowly to prevent the airflow from blowing out the powder. Then the powder has to be diluted with saline water before injecting.
Whey protein concentrate: 104 Whole egg: 100 Cow milk: 91 Beef: 80 Casein: 77 Soy: 74 Wheat gluten: 64 By combining different foods it is possible to maximize the score, because the different components favor each other:
The development of a germanium-wire based anode that more than doubles the capacity of lithium-ion batteries was reported in 2014. In the same year, Lee et al. reported that defect-free crystals of graphene large enough to have electronic uses could be grown on, and removed from, a germanium substrate. Arsenic and antimony are not semiconductors in their standard states. Both form type III-V semiconductors (such as GaAs, AlSb or GaInAsSb) in which the average number of valence electrons per atom is the same as that of Group 14 elements, but they have direct band gaps. These compounds are preferred for optical applications. Antimony nanocrystals may enable lithium-ion batteries to be replaced by more powerful sodium ion batteries. Tellurium, which is a semiconductor in its standard state, is used mainly as a component in type II/VI semiconducting-chalcogenides; these have applications in electro-optics and electronics. Cadmium telluride (CdTe) is used in solar modules for its high conversion efficiency, low manufacturing costs, and large band gap of 1.44 eV, letting it absorb a wide range of wavelengths. Bismuth telluride (Bi2Te3), alloyed with selenium and antimony, is a component of thermoelectric devices used for refrigeration or portable power generation. Five metalloids – boron, silicon, germanium, arsenic, and antimony – can be found in cell phones (along with at least 39 other metals and nonmetals). Tellurium is expected to find such use. Of the less often recognised metalloids, phosphorus, gallium (in particular) and selenium have semiconductor applications.
In 1981, a commercial involving a train was made, the musical theme was "La Colegiala" composed by Rodolfo Aicardi. Due to the enormous popularity of Nescafé, during the Second World War, "all the production of the American plant was reserved only for the use of the military". In Ecuador, a Boeing 737-200 from the AeroGal company was painted red to promote the brand. In Chile, since 2009 the brand has sponsored and helped to restore a well-known Chilean theater that was in decline, making it the first Nescafé theater in the world and naming it the Nescafé Theater of the Arts. In previous years, the brand was sponsoring different stars of Canal 13, such as Esta Noche Fiesta and Tuesday 13, the 123 Nescafé competition and was for some time the sponsor of different campaigns of the Chilean Telethon, returning as sponsor to the campaign in 2011. In turn, its variant Nescafé Dolca was sponsor of Una Vez Más of Canal 13. In the Philippines, an advertising commercial was released in 2020 with their newest jingle and slogan, "Babangon tayo, susulong tayo" ("We will rise, we will advance"). English rock band Muse successfully sued Nescafé in 2003 when their song "Feeling Good" was used in a television ad without permission and donated the £500,000 compensation to Oxfam.
=== Reference ranges === The European Food Safety Authority (EFSA) recommends a dietary allowance of 70 μg per day selenium intake for adults. In the US, the Dietary Reference Intake for adults is 55 μg/day. In the UK it is 75 μg/day for adult males and 60 μg/day for adult females. The 55 μg/day recommendation is based on the full expression of plasma glutathione peroxidase. Selenoprotein P is a better indicator of selenium nutritional status, and full expression of it would require more than 66 μg/day.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.